Completed PHASE2 INTERVENTIONAL 1-arm NCT00186628

Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD

An Open-label, Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of Chronic Graft Versus Host Disease After TLI/ARG Nonmyeloablative Allogeneic Stem Cell Transplantation

Sponsor: National Cancer Institute (NCI)

Conditions Leukemia, Mast-Cell Mantle-cell Lymphoma

Interventions Acetaminophen Anti-thymoglobulin, rabbit (ATG, rabbit ATG) Cyclosporine Diphenhydramine Filgrastim Granisetron Hydrocortisone Mycophenylate mofetil Rituximab Solumedrol Total lymphoid irradiation

Updated 6 times since 2017 Last updated: Oct 20, 2017 Started: Jun 30, 2005 Primary completion: Nov 30, 2010 Completion: Dec 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Leukemia, Mast-Cell and Mantle-cell Lymphoma, this trial is completed. The trial is conducted by National Cancer Institute (NCI) and has accumulated 6 data snapshots since 2005. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Dec 2017 — Jun 2018 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Dec 2017 [monthly]

Completed PHASE2

First recorded

Jun 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Institute (NCI)
Stanford University
The Leukemia and Lymphoma Society

Data source: Stanford University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Stanford, United States